
Photo Credit: Treedeo.St Studios
Scientific Frontline: "At a Glance" Summary
- Main Discovery: The intensity of the acute psychedelic experience or "high" induced by ketamine does not correlate with its success in treating severe alcohol use disorder.
- Methodology: Researchers performed a secondary analysis of the KARE clinical trial involving 96 adults, who received three weekly intravenous ketamine infusions alongside psychological therapy, and compared their reported subjective psychoactive effects against alcohol abstinence rates.
- Key Data: While participants consistently reported profound experiences such as altered reality and out-of-body sensations, the magnitude of these subjective effects did not predict the percentage of days abstinent over the six-month follow-up period.
- Significance: This study challenges the prevailing hypothesis that the "mystical" or psychoactive experience drives ketamine's therapeutic efficacy, suggesting that benefits likely stem from pharmacological mechanisms like neuroplasticity or altered brain network connectivity.
- Future Application: These findings indicate that clinical protocols for ketamine-assisted therapy do not need to prioritize maximizing the psychedelic experience to achieve therapeutic reduction in alcohol relapse.
- Branch of Science: Addiction Psychiatry and Neuroscience
- Additional Detail: Participants showed no significant tolerance to the drug's subjective effects over the short dosing schedule, experiencing consistently strong psychoactive responses across all three sessions.
.jpg)

.jpg)








.jpg)

